SQLite Web: event_store.db

Update row 39547 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-14T02:04:49.876253+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:1d87cf7b897220f9","evidence_event_ids":["evt_b8c2eee5ea41"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000031.txt","as_of":"2026-04-14T02:04:49.876253+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000031.txt","company":"UNITED THERAPEUTICS Corp","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000031.txt","article_chars":4999,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_1770ac526bf126fa","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000031.txt","content_type":"text/plain","enriched_at":"2026-04-14T02:19:17.030441+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000031.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000031.txt","source_event_id":"evt_b8c2eee5ea41","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"5854bfa236f1809a","kind":"sec_filing","published_at":"20260413","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-13","2026-04-10","2025-11-07","2027-03-17","2026-12-31","1999-03-24"],"entities":[{"asset_class":"equity","name":"UNITED THERAPEUTICS Corp","relevance":"high","symbol":"UTHR","type":"issuer"},{"asset_class":"equity","name":"Martine A. Rothblatt","relevance":"high","symbol":"","type":"reporting_person"},{"asset_class":"equity","name":"United Therapeutics Corporation","relevance":"low","symbol":"UTHR","type":"issuer_address_entity"}],"event_type":"other","information_gaps":["The signal text does not clearly enumerate the total number of options exercised and total number of shares sold across all lines; it shows multiple transaction lines but without an explicit consolidated total.","The excerpt includes repeated/partial weighted-average price statements; exact mapping of each price range segment to specific share quantities is not fully clear from the provided cleaned text.","The filing type is identified as Form 4, but the specific transaction codes (e.g., M/S/I/D) are not explained in the provided text beyond the raw line indicators."],"key_facts":["SEC filing is Form 4 (SEC Act: 1934 Act) for United Therapeutics Corp.","Filing accession number: 0001106578-26-000031; filed as of date: 2026-04-13; conformed period of report: 2026-04-10.","Reporting owner: Martine A. Rothblatt (Chairperson & CEO) for United Therapeutics Corp.","The filing states the option exercise and sale of resulting common shares was pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.","The plan is stated to continue until the earlier of: (a) exercise of 1,734,410 stock options (all expire March 17, 2027) or (b) December 31, 2026.","The filing states the transaction was executed in multiple trades at prices ranging from $566.44 to $573.11 (weighted average price reported above each line).","The filing includes multiple common stock transaction lines dated 2026-04-10 with quantities and prices shown in the text (e.g., 9500.00 shares at $64500.00 proceeds line appears; other lines show quantities such as 442.00, 2105.00, 3183.00, etc.)."],"numeric_claims":[{"label":"Form 4 filed as of date","value":"2026-04-13"},{"label":"Conformed period of report","value":"2026-04-10"},{"label":"10b5-1 plan adoption date","value":"2025-11-07"},{"label":"Plan end condition (option exercise count)","value":"1,734,410 stock options"},{"label":"Option expiration date (per plan)","value":"2027-03-17"},{"label":"Plan end condition (date)","value":"2026-12-31"},{"label":"Trade price range stated","value":"$566.44 to $573.11"}],"primary_claim":"Form 4 shows Martine A. Rothblatt exercised stock options and sold common stock on 2026-04-10 under a 10b5-1 trading plan adopted November 7, 2025.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"United Therapeutics (UTHR) disclosed in an SEC Form 4 filed on 2026-04-13 that reporting person Martine A. Rothblatt exercised stock options and sold resulting common shares. The transactions were executed under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07.","topics":["SEC Form 4","insider trading","10b5-1 plan","stock option exercise","common stock sale"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 UNITED THERAPEUTICS Corp \u00b7 Filed 20260413","ticker":"UTHR","tickers":["UTHR"],"title":"UTHR filed 4","url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000031.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel